A5058447878- Nanoplatforms for cancer theranostics
- Cancer Immunotherapy and Biomarkers
- RNA Research and Splicing
- MicroRNA in disease regulation
- Circular RNAs in diseases
- Cancer, Stress, Anesthesia, and Immune Response
Xiamen University
2021-2023
Abstract Tamoxifen resistance (TamR) prevents ER-positive breast cancer patients from benefitting endocrine therapy, and miR-221 or miR-222 plays vital roles in inducing TamR. In this study, we designed synthetic sponges to reverse TamR by targeting these two miRs. First, established a tamoxifen resistant cell line (MCF-7 ), verified the high expressing level of miRs cells. inhibitors rendered MCF-7 cells responsive tamoxifen. Next, miR-221/222 sponge, which contains total 8 multi-antisense...
Background: Durable responses to immune-checkpoint blocking therapy (ICT) targeting programmed cell death protein-1/ligand-1 (PD-1/PD-L1) have improved outcomes for patients with triple negative breast cancer (TNBC). Unfortunately, only 19– 23% of benefit from ICT. Hence, non-invasive strategies evaluating and selecting who will ICT are critical issues TNBC immunotherapy. Methods: We developed a novel nanoparticle-Atezolizumab (NPs-Ate) consisting indocyanine green (ICG),...